Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 13Liver Neoplasms 6Neoplasm Metastasis 4Recurrence 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Neoplasms 1Melanoma 1Lung Metastases 1Colorectal Neoplasms 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Chemoembolization, Therapeutic × Clear all
NCT01336985 2019-12-17

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
5 enrolled
DermatologicGastrointestinal

Liver Neoplasms, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡